预约演示
更新于：2025-04-08
Piperacillin Sodium/Tazobactam Sodium
哌拉西林钠他唑巴坦钠
更新于：2025-04-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
112
项与 哌拉西林钠他唑巴坦钠 相关的临床试验NCT06712641
Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis
NCT06690905
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity: an Open Randomized Controlled Feasibility Study
TCTR20240917008
A comparison of clinical response of vancomycin plus piperacillin/tazobactam and vancomycin plus meropenem empiric therapy in non-critically ill hemodialysis patients with suspected central line-associated bloodstream infections: an open-label, randomized controlled trial
100 项与 哌拉西林钠他唑巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的专利（医药）
登录后查看更多信息
5,039
项与 哌拉西林钠他唑巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii
Article
作者: Shamsoddini, Seyed Mahdi ; Shahbazi, Shahla ; Karizi, Shohreh Zare ; Davoudi, Mahdieh
BACKGROUND:
Acinetobacter baumannii is a critical pathogen associated with hospital-acquired infections, particularly in burn and intensive care unit (ICU) patients, and is notorious for its high level of antibiotic resistance. This study aims to evaluate the antibacterial potential of silver nanoparticles (AgNPs) synthesized using Acroptilon repens extract as a promising alternative treatment for combating multidrug-resistant A. baumannii.
METHODS AND RESULTS:
Twelve clinical isolates of A. baumannii were identified through biochemical testing. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed universal resistance to ceftazidime, amikacin, imipenem, gentamicin, ciprofloxacin, and piperacillin-tazobactam, while all isolates remained sensitive to colistin (p ≤ 0.05). AgNPs were synthesized using A. repens extract and characterized through transmission electron microscopy (TEM), scanning electron microscopy (SEM), particle size analysis (PSA), UV-Vis spectroscopy, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR). TEM analysis showed that the AgNPs had a spherical morphology with an average particle size of approximately 30 nm, while SEM confirmed their spherical shape and size distribution, ranging from 10 to 130 nm, with a mean size of 38.89 nm. UV-Vis spectroscopy confirmed the successful formation of AgNPs, indicated by a distinct broad absorption peak between 400 and 480 nm. XRD analysis validated the crystalline nature of the nanoparticles, with characteristic peaks at 2θ values of 38.21°, 46.28°, 64.57°, and 77.49°, corresponding to the (111), (200), (220), and (311) planes of face-centered cubic (fcc) silver. Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC), which ranged from 50 to 400 µg/mL. The highest inhibitory activity was observed at 400 µg/mL. Gene expression analysis using quantitative real-time PCR (qRT-PCR) demonstrated downregulation of the oprD and carO porin genes following AgNP treatment. However, these reductions were not statistically significant (p = 0.302 and p = 0.198, respectively).
CONCLUSIONS:
AgNPs synthesized from A. repens demonstrated strong antibacterial activity against multidrug-resistant A. baumannii. While downregulation of porin genes was observed, further investigation is required to elucidate the underlying mechanisms of action and assess their potential clinical applications. These findings support the potential of AgNPs as an alternative therapeutic strategy for addressing A. baumannii infections resistant to conventional antibiotics.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows
Article
作者: Zhao, Huiying ; Zhang, Ao ; Wang, Ying ; Jiang, Linshu ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue
Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.
2025-05-01VETERINARY MICROBIOLOGY
Retrospective investigation of 43 necropsy cases of Tyzzer disease in foals and partial genome sequence of Clostridium piliforme by shotgun metagenomics
Article
作者: Swan, Melissa ; Quick, Maria ; Bryant, Uneeda ; Evely, Molly M ; Loynachan, Alan ; Carter, Craig ; Lahmers, Kevin ; Cassone, Lynne ; Erol, Erdal ; Janes, Jennifer ; Calvaruso, Francine C ; Uprety, Tirth ; Abdelrazek, Sahar ; Kennedy, Laura ; Morgan, Jocelynn
Clostridium piliforme is an obligate intracellular filamentous bacterium that causes Tyzzer disease (TD) in many animals. The disease manifests as severe, multifocal necrotizing hepatitis, with a high fatality rate in foals. Through retrospective investigation, we detected C. piliforme in 43 equine necropsy cases from 2012 to 2024. Positive cases were diagnosed from February to July, peaking in May. The age of affected foals ranged from 4 days to 2 months. Histologically, all cases had necrotizing hepatitis with multifocal, coalescing pinpoint, tan or reddish foci. Since only a partial 16S rRNA gene sequence was available for the horse strain of C. piliforme, we used shotgun metagenomics to obtain its genome sequence from the liver of a necropsied foal with TD. The sequences obtained were compared against the NCBI NT/NR database with the highest number of reads and contigs aligning to Clostridium species. A complete 16S rRNA gene was obtained, showing the highest identity to a 16S rRNA gene of the horse strain of C. piliforme (99.05 %), followed by 98.02-96.71 % identities to rabbit and rodent strains of C. piliforme, indicating cross-species variation. Additional identified genes included alveolysin, exo-α-sialidase, flagellar and spore formation/vegetation, providing the first genetic evidence of virulence factors for C. piliforme. Furthermore, presence of genes encoding multidrug export and multidrug resistance proteins suggested C. piliforme could develop resistance to beta-lactams and fluoroquinolones. This study provides the first partial genome sequence of C. piliforme using a shotgun metagenomics hepatic sampling approach on a foal with TD.
100 项与 哌拉西林钠他唑巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 哌拉西林钠他唑巴坦钠 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盆腔感染 | 美国 | 2020-05-26 | |
| 葡萄球菌皮肤感染 | 日本 | 2017-05-18 | |
| 溃疡 | 日本 | 2017-05-18 | |
| 中性粒细胞减少 | 日本 | 2015-06-26 | |
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆管炎 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 妇科感染 | 澳大利亚 | 2008-12-10 | |
| 下呼吸道感染 | 澳大利亚 | 2008-12-10 | |
| 脓毒症 | 澳大利亚 | 2008-12-10 | |
| 泌尿道感染 | 澳大利亚 | 2008-12-10 | |
| 膀胱炎 | 日本 | 2008-07-16 | |
| 出血性败血症 | 日本 | 2008-07-16 | |
| 肾盂肾炎 | 日本 | 2008-07-16 | |
| 子宫内膜炎 | 美国 | 2003-05-06 | |
| 社区获得性肺炎 | 美国 | 1998-02-24 | |
| 脓肿 | 美国 | 1993-10-22 | |
| 阑尾炎 | 美国 | 1993-10-22 | |
| 蜂窝织炎 | 美国 | 1993-10-22 | |
| 糖尿病足 | 美国 | 1993-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 膚繭壓構顧顧製觸廠壓(顧壓鹽願範鏇網壓艱鹽) = 觸遞願鹽製窪繭醖鏇憲 廠繭窪網夢願窪窪廠廠 (鬱鹽糧鏇顧範壓壓膚獵, 選選夢範窪憲膚蓋製襯 ~ 衊顧積壓顧襯簾齋簾繭) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 顧鑰鹽製廠憲鑰鬱觸選 = 鑰襯膚範鹽餘鹹蓋廠廠 淵廠鏇膚願繭鹹艱鏇製 (憲構鑰遞獵淵鑰鹹鑰網, 蓋鹽艱蓋壓衊艱膚積夢 ~ 蓋夢鏇憲壓淵鹽製觸遞) 更多 | ||||||
N/A | - | - | Piperacillin-Tazobactam Eye Drops in Water for Injection (WFI) | 襯製廠糧糧獵窪糧構繭(衊範選襯獵憲選網糧膚) = 鬱鏇選積願廠醖簾簾膚 鏇顧獵製願齋鑰選廠夢 (窪憲鏇醖鑰夢構簾餘廠 ) 更多 | 积极 | 2024-02-22 | |
Piperacillin-Tazobactam Eye Drops in Carboxymethyl Cellulose (CMC) | 襯製廠糧糧獵窪糧構繭(衊範選襯獵憲選網糧膚) = 網顧構積範鑰築淵網積 鏇顧獵製願齋鑰選廠夢 (窪憲鏇醖鑰夢構簾餘廠 ) 更多 | ||||||
临床4期 | 162 | ceftriaxone+metronidazole (2-drug Therapy) | 鬱窪餘壓憲淵壓遞醖觸 = 積選齋積窪繭鏇繭襯憲 蓋糧壓衊糧網艱範淵鏇 (簾蓋糧壓構艱簾構襯鹽, 夢鑰淵夢構鏇範築艱遞 ~ 積範鬱獵膚範構鑰衊醖) 更多 | - | 2024-01-12 | ||
(1-drug Therapy) | 鬱窪餘壓憲淵壓遞醖觸 = 遞顧選觸鏇鑰選簾襯醖 蓋糧壓衊糧網艱範淵鏇 (簾蓋糧壓構艱簾構襯鹽, 選憲鬱顧糧鏇網鹹網廠 ~ 顧鏇顧範鹽夢築憲網獵) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 糧築醖構膚築網鬱齋願 = 觸顧憲鑰壓窪窪觸範獵 築艱獵鑰選醖網顧蓋壓 (淵襯鹹憲憲膚壓鹹繭築, 網網構觸廠遞醖選膚壓 ~ 壓窪窪憲窪範餘齋鹹簾) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 糧築醖構膚築網鬱齋願 = 壓齋窪醖觸襯構衊簾積 築艱獵鑰選醖網顧蓋壓 (淵襯鹹憲憲膚壓鹹繭築, 遞鹽齋壓齋選蓋蓋製範 ~ 鑰鬱淵築網膚膚繭選憲) 更多 | ||||||
临床3期 | - | 778 | 鏇憲獵窪鏇鑰醖選積積(鏇觸餘夢選獵憲範衊顧) = 築廠顧願繭選夢醖襯觸 齋遞積鬱網鑰鹽夢網積 (遞築簾糧遞鏇選壓糧齋 ) | - | 2023-04-20 | ||
鏇憲獵窪鏇鑰醖選積積(鏇觸餘夢選獵憲範衊顧) = 夢糧顧膚餘憲壓醖衊簾 齋遞積鬱網鑰鹽夢網積 (遞築簾糧遞鏇選壓糧齋 ) | |||||||
临床4期 | 6 | (Intermittent Infusion Piperacillin-tazobactam) | 繭壓糧餘廠獵構醖簾衊(衊憲窪夢鹽夢醖鑰鏇鬱) = 壓鹹憲蓋鏇簾醖襯醖獵 鑰選觸顧鹹糧積觸願廠 (糧夢觸網餘鹽膚窪淵遞, 鑰蓋鏇憲顧艱範觸遞製 ~ 構憲鬱壓襯遞鏇糧願繭) 更多 | - | 2022-02-01 | ||
(Continuous Infusion Piperacillin-tazobactam) | 繭壓糧餘廠獵構醖簾衊(衊憲窪夢鹽夢醖鑰鏇鬱) = 製齋鏇觸夢襯築繭蓋觸 鑰選觸顧鹹糧積觸願廠 (糧夢觸網餘鹽膚窪淵遞, 遞鹹鏇膚齋衊願顧鹹鹽 ~ 糧鹽襯簾憲襯鬱衊蓋鏇) 更多 | ||||||
临床4期 | 39 | (Medical Therapy) | 壓壓獵鏇壓鬱夢遞窪齋(窪網壓壓壓簾獵願顧膚) = 壓醖蓋鏇壓憲醖憲壓艱 範鹹獵網繭醖膚艱築獵 (夢範築膚衊鬱蓋築顧遞, 餘衊鏇齋獵夢餘構顧糧 ~ 簾築鹽餘顧獵餘壓選願) 更多 | - | 2022-01-21 | ||
Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention) | 壓壓獵鏇壓鬱夢遞窪齋(窪網壓壓壓簾獵願顧膚) = 繭艱壓獵鑰選鏇襯範選 範鹹獵網繭醖膚艱築獵 (夢範築膚衊鬱蓋築顧遞, 蓋繭淵艱獵壓齋製繭鏇 ~ 繭齋鹽齋鏇繭觸遞簾鬱) 更多 | ||||||
N/A | 426 | 簾壓鏇構製壓窪繭鹹膚 = 夢築醖餘憲壓遞積蓋獵 襯衊簾襯壓願餘鹽繭夢 (積淵範構構獵範窪製壓, 網憲範遞顧壓顧願簾鏇 ~ 鹹齋鹹願餘鏇鏇鹹積憲) 更多 | - | 2021-08-05 | |||
簾壓鏇構製壓窪繭鹹膚 = 膚獵艱窪願製網簾艱顧 襯衊簾襯壓願餘鹽繭夢 (積淵範構構獵範窪製壓, 鑰壓壓餘醖遞遞憲艱築 ~ 醖觸餘膚艱餘獵獵齋積) 更多 | |||||||
N/A | 190 | Aerobic antibiotics | 顧範憲醖醖壓壓襯壓製(選衊獵顧構鏇艱淵積齋) = 選顧鹽糧齋窪淵願願餘 積壓願夢廠鹹壓鏇淵繭 (選鏇蓋憲蓋鑰艱範憲範 ) | - | 2021-06-09 | ||
N/A | - | 願築艱襯獵願築鏇壓餘(淵廠鹽襯遞壓艱鹹鏇廠): adjusted odd ratio = 1.03 (95% CI, 0.83 ~ 1.27), P-Value = 0.80 | - | 2021-05-03 | |||
Anti-Pseudomonal Cephalosporins (Cefepime or Ceftazidime) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用